# The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study

> **NCT05258643** · NA · UNKNOWN · sponsor: **Universitair Ziekenhuis Brussel** · enrollment: 150 (estimated)

## Conditions studied

- Complement Abnormality
- Peripheral Blood Mononuclear Cells
- Covid19

## Interventions

- **OTHER:** Blood analysis

## Key facts

- **NCT ID:** NCT05258643
- **Lead sponsor:** Universitair Ziekenhuis Brussel
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-09-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2022-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05258643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05258643, "The Role of Natural Killer, Complement and T-lymphocytes in COVID-19 Disease, a Prospective Monocentric Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05258643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*